Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospices Civils de Lyon
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged ≥ 18 years
Signed written informed consent
Patient with BRAF V600 mutated metastatic or unresectable melanoma histologically confirmed
BRAFi/MEKi treatment indication
Patient with skin tumor (excluded face and skinfold) available for biopsy
Measurable disease as defined by RECIST v1.1 criteria
Patient affiliated to or a beneficiary of a social security category
You may not be if
Ocular melanoma
Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study
Pregnant or nursing (lactating) women
Patients protected by law
Clareo Health | Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma
